US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VictoryShares US Discovery Enhanced Volatility Wtd ETF

51.03

0.0000

Volume:- -

Turnover:- -

Market Cap:25.52M

PE:- -

High:51.03

Open:51.03

Low:51.03

Close:51.03

52wk High:60.63

52wk Low:50.07

Shares:500.00K

Float Shares:500.00K

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Press Release: Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

Press Release: Median Technologies Reports Full-year 2024 Financial Results

Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CSF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","market":"US","secType":"STK","nameCN":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","latestPrice":51.03,"timestamp":1757448000000,"preClose":51.03,"halted":0,"volume":0,"delay":0,"floatShares":500000,"shares":500000,"eps":0,"marketStatus":"Post-Mkt","change":0,"latestTime":"09-09 18:10:29 EDT","open":51.03,"high":51.03,"low":51.03,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1757462400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":51.03,"sharesOutstanding":500000,"nav":51.331892,"aum":25665950,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","floatShares":500000,"roa":"--","roe":"--","lyrEps":0,"shares":500000,"dividePrice":0,"high":51.03,"amplitude":0,"preClose":51.03,"low":51.03,"week52Low":50.07,"pbRate":"--","week52High":60.63,"institutionHeld":0,"latestPrice":51.03,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":51.03,"prevYearClose":54.8761,"prevWeekClose":51.03,"prevMonthClose":51.03,"prevQuarterClose":51.03,"fiveDayClose":51.03,"twentyDayClose":51.03,"sixtyDayClose":51.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-24","symbol":"CSF","reason":null,"defaultRemindTime":1745501400000,"announcedDate":"2025-04-23","type":"delisting","dateTimestamp":1745467200000},{"date":"2025-04-10","symbol":"CSF","amount":0.053873,"announcedDate":"2025-04-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-10","defaultRemindTime":1744291800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-11","payableDate":"2025-04-10","currency":"USD","dateTimestamp":1744257600000,"payDate":"2025-04-11"},{"date":"2025-03-10","symbol":"CSF","amount":0.09736,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-10","defaultRemindTime":1741613400000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-11","payableDate":"2025-03-10","currency":"USD","dateTimestamp":1741579200000,"payDate":"2025-03-11"},{"date":"2024-12-12","symbol":"CSF","amount":0.194215,"announcedDate":"2024-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-12","defaultRemindTime":1734013800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-13","payableDate":"2024-12-12","currency":"USD","dateTimestamp":1733979600000,"payDate":"2024-12-13"},{"date":"2024-11-07","symbol":"CSF","amount":0.016451,"announcedDate":"2024-11-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-07","defaultRemindTime":1730989800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-08","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730955600000,"payDate":"2024-11-08"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSF\",market:\"US\",,,undefined,":[{"executeDate":"2017-01-17","recordDate":"2017-01-19","paymentDate":"2017-01-20","value":0.0124628,"currency":"USD"},{"executeDate":"2017-02-14","recordDate":"2017-02-16","paymentDate":"2017-02-17","value":0.0180041,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-21","value":0.072161,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-19","value":0.02261,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-16","value":0.048374,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSF\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2563072015","title":"FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2563072015","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563072015?lang=en_us&edition=fundamental","pubTime":"2025-08-30 05:00","pubTimestamp":1756501200,"startTime":"0","endTime":"0","summary":"LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatme","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/29/3141816/0/en/FDA-Approves-LEQEMBI-IQLIK-lecanemab-irmb-Subcutaneous-Injection-for-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDR","BK4080","ARIA","CAA","CSF","MCI","BK4110","AD","BK4132","HF","AAIC"],"gpt_icon":0},{"id":"2559964326","title":"Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2559964326","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559964326?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:15","pubTimestamp":1755202500,"startTime":"0","endTime":"0","summary":"Announced CNSide CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug.  14, 2025  (GLOBE NEWSWIRE) -- Plus Therapeu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133893/0/en/Plus-Therapeutics-Reports-Second-Quarter-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCI","LENZ","BK4202","CNS","BK4135","BK4539","BK4007","CSF"],"gpt_icon":0},{"id":"2559795431","title":"Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2559795431","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559795431?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:30","pubTimestamp":1755171000,"startTime":"0","endTime":"0","summary":"CNSide can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations CNSide may catalyze LM treatment initiation, allow physicians to ada","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133364/0/en/Plus-Therapeutics-Presents-Positive-CNSide-CSF-Assay-Platform-Results-at-the-2025-SNO-ASCO-CNS-Metastases-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CSF","BK4135","BK4007","BK4139","LENZ","CNS"],"gpt_icon":0},{"id":"2559602868","title":"ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2559602868","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559602868?lang=en_us&edition=fundamental","pubTime":"2025-08-13 19:00","pubTimestamp":1755082800,"startTime":"0","endTime":"0","summary":"U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, enhancing program’s potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer’s Disease Progressing on Schedule: Ov","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/13/3132444/0/en/ProMIS-Neurosciences-Announces-Second-Quarter-2025-Financial-Results-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARIA","LU2125909916.SGD","LU0728928796.USD","PK","LU1923622291.USD","AD","BK4526","LU1169589451.USD","BK4600","BK4218","BK4170","LU0757428866.USD","USA","LU1815336091.USD","LU2125909759.SGD","CSF","LU2211815571.USD","PD","MSA","LU1169590202.USD","BK4143","BK4595","BK4023","BK4181","LU0053671581.USD"],"gpt_icon":1},{"id":"2558492646","title":"Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2558492646","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558492646?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:00","pubTimestamp":1754996400,"startTime":"0","endTime":"0","summary":"Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/12/3131555/0/en/Passage-Bio-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRN","CSF"],"gpt_icon":0},{"id":"2557859665","title":"Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2557859665","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557859665?lang=en_us&edition=fundamental","pubTime":"2025-08-08 04:05","pubTimestamp":1754597100,"startTime":"0","endTime":"0","summary":"Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson’s disease Data from the Phase 2 study of VTX2735 in patients with recurre","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/07/3129657/0/en/Ventyx-Biosciences-Reports-Second-Quarter-2025-Financial-Results-and-Highlights-Recent-Corporate-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","CSF","BK4097","BK4135","IBD","VTYX","BK4007","LU2065732104.USD","CNS"],"gpt_icon":0},{"id":"2555806838","title":"Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2555806838","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555806838?lang=en_us&edition=fundamental","pubTime":"2025-07-31 19:30","pubTimestamp":1753961400,"startTime":"0","endTime":"0","summary":"CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems Company will expand testing services and broaden r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/31/3124879/0/en/Plus-Therapeutics-Provides-US-Launch-Update-for-its-CNSide-Diagnostic.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","CSF","CNS","BK4202","BK4539","BK4139","BK4007","LENZ","BK4135"],"gpt_icon":0},{"id":"2555056899","title":"Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2555056899","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555056899?lang=en_us&edition=fundamental","pubTime":"2025-07-29 19:30","pubTimestamp":1753788600,"startTime":"0","endTime":"0","summary":"- Zervimesine’s impact on debilitating DLB behavioral symptoms highlighted in podium presentation -- Plasma p-tau217 levels can identify Alzheimer’s patients most likely to benefit from zervimesine tr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/29/3123138/0/en/Cognition-Therapeutics-Presents-Data-at-AAIC-Highlighting-Broad-Neurological-Impact-of-Zervimesine-CT1812-in-Dementia-with-Lewy-Bodies-and-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","LU0205193047.USD","AAIC","DLB","BK4007","CDR","CSF","CAF","BK4110","LENZ","LU0240878834.USD","LU0240877869.USD","BK4139","LU0348723411.USD","LU0345774391.USD","LU0345774631.USD","BK4539","BK4080","LU0205194284.USD","CGTX"],"gpt_icon":0},{"id":"2550264240","title":"Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2550264240","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550264240?lang=en_us&edition=fundamental","pubTime":"2025-07-10 19:30","pubTimestamp":1752147000,"startTime":"0","endTime":"0","summary":"The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases Presentations will highlight the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/10/3113140/0/en/Plus-Therapeutics-Announces-Two-CNSide-Presentations-at-the-Upcoming-SNO-ASCO-CNS-Metastases-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","BK4539","LENZ","CSF","BK4135","CNS"],"gpt_icon":0},{"id":"2533831839","title":"Press Release: Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2533831839","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533831839?lang=en_us&edition=fundamental","pubTime":"2025-05-07 19:00","pubTimestamp":1746615600,"startTime":"0","endTime":"0","summary":"-- On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 --. -- Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 --. WATERTOWN, Mass., May 07, 2025  -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2025, and provided updates on its recent progress.-- Final analysis from IGNITE Phase 2 clinical trial planned for second. quarter of 2025: The Company plans to report the final analysis from the. IGNITE Phase 2 clinical trial, including all patients at 12 months dosed. with either 20 mg/kg or 40 mg/kg of iluzanebart in the second quarter of. iluzanebart in ALSP and expects to share an update on its progress when. positive data from its completed Phase 1 clinical trial evaluating. cohorts, including 8 SAD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","LU1169590202.USD","BK4023","VIGL","PK","BK4588","BK4181","BK4604","VG","BK4099","TM","BK4139","LU1169589451.USD","BK4555","BK4213","BK4218","BK4585","03160","CSF"],"gpt_icon":0},{"id":"2531750647","title":"Press Release: Median Technologies Reports Full-year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2531750647","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531750647?lang=en_us&edition=fundamental","pubTime":"2025-04-29 23:45","pubTimestamp":1745941500,"startTime":"0","endTime":"0","summary":"-- Returns to FY revenue growth in 2024 , with acceleration in H2. -- eyonis Lung Cancer Screening  pivotal REALITY and RELIVE studies. \"As we move through 2025, we expect to reach further value inflection points including U.S. 510 filing of eyonis LCS in May, paving the way for commercial launch by the end of the year, and the European CE marking filing in June. Our recent major iCRO agreement with a Top 3 pharma group is already providing strong traction for future growth. After three years of technology investments, iCRO can capitalize on its service differen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CSF","BK4099","TM","BK4604","BK4555","03160","BK4588"],"gpt_icon":0},{"id":"2525814141","title":"Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2525814141","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525814141?lang=en_us&edition=fundamental","pubTime":"2025-04-08 23:00","pubTimestamp":1744124400,"startTime":"0","endTime":"0","summary":"CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by neuroinflam","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057821/0/en/Cerevance-Presents-Positive-Results-from-Phase-1-Study-of-CVN293-at-American-Academy-of-Neurology-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4178","BK4107","BK4117","CNS","BK4135","AFG","CSF","AAN"],"gpt_icon":0},{"id":"2524085052","title":"Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation","url":"https://stock-news.laohu8.com/highlight/detail?id=2524085052","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524085052?lang=en_us&edition=fundamental","pubTime":"2025-04-04 19:00","pubTimestamp":1743764400,"startTime":"0","endTime":"0","summary":"–Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/04/3055854/0/en/Arvinas-Presents-First-in-Human-Data-for-Investigational-Oral-PROTAC-ARV-102-Demonstrating-Blood-Brain-Barrier-Penetration-and-Central-and-Peripheral-LRRK2-Degradation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","PSP","LU1169589451.USD","LU1169590202.USD","PD","BK4023"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}